15 To 23 Amino Acid Residues In Defined Sequence Patents (Class 530/326)
  • KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY
    Publication number: 20140286864
    Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.
    Type: Application
    Filed: December 17, 2013
    Publication date: September 25, 2014
    Applicants: Bracco Suisse SA, Dyax Corp.
    Inventors: AARON K. SATO, DANIEL J. SEXTON, DANIEL T. DRANSFIELD, ROBERT CHARLES LADNER, CHRISTOPHE ARBOGAST, PHILIPPE BUSSAT, HONG FAN, SUDHA KHURANA, KAREN E. LINDER, EDMUND R. MARINELLI, PALANIAPPA NANJAPPAN, ADRIAN D. NUNN, RADHAKRISHNA K. PILLAI, SIBYLLE POCHON, KONDAREDDIAR RAMALINGAM, AJAY SHRIVASTAVA, BO SONG, ROLF E. SWENSON, MATHEW A. VON WRONSKI, FENG YAN
  • Compositions Useful For The Treatment Of Gastrointestinal Disorders
    Publication number: 20140287001
    Abstract: This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 25, 2014
    Inventor: Kunwar Shailubhai
  • Synthetic peptide constructs for the diagnosis and treatment of periodontis associated with
    Patent number: 8841420
    Abstract: The present invention relates to an oral composition and an immunogenic composition for the suppression of the pathogenic effects of the intra-oral bacterium Porphyromonas gingivalis associated with periodontal disease.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: September 23, 2014
    Assignee: The University of Melbourne
    Inventors: Eric Charles Reynolds, Neil Martin O'Brien-Simpson, Nada Slakeski
  • Antidiabetic compounds
    Patent number: 8841413
    Abstract: The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-1 receptor agonistic activity.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: September 23, 2014
    Assignee: Cadila Healthcare Limited
    Inventors: Rajesh H. Bahekar, Braj Bhushan Lohray, Vidya Bhushan Lohray, Mukul R. Jain, Kaushik M. Banerjee, Pankaj Ramanbhai Patel
  • Viral/bacterial toxin polypeptides and methods of using same
    Patent number: 8841253
    Abstract: The invention features methods for identifying compounds that inhibit cell death, and methods for identifying compounds that promote cell death, by blocking or accelerating, respectively, the translocation of the catalytic domain of toxins or transcription factors through the endosomal membrane into the cytosol of a cell. Also featured are methods for inhibiting cell death that include the administration of polypeptides that include a toxin consensus sequence recognized by one or more components of the cytosolic translocation factor complex.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: September 23, 2014
    Assignee: Boston Medical Center Corporation
    Inventors: John R. Murphy, Ryan Ratts
  • USE OF MYCOBACTERIUM AVIUM PARATUBERCULOSIS PEPTIDES TO DIAGNOSE TYPE 1 DIABETES
    Publication number: 20140271701
    Abstract: The present invention concerns antibodies recognizing Mycobacterium avium paratuberculosis epitopes able to cross-reacting with the beta-cell antigen ZnT8 to be used as early biomarkers of type 1 diabetes, epitopes for in vitro prognostic and diagnostic methods suitable to reveal a risk to develop type 1 diabetes, therapies for the prevention of T1D by avoiding, controlling or monitoring Mycobacterium paratuberculosis infection.
    Type: Application
    Filed: October 25, 2012
    Publication date: September 18, 2014
    Inventors: Leonardo Antonio Sechi, Roberto Mallone
  • ND2 PEPTIDES AND METHODS OF TREATING NEUROLOGICAL DISEASE
    Publication number: 20140274906
    Abstract: The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 307-321 or 310-321 of ND2. Peptides including, overlapping or from within this region can be used to inhibit ND2 interaction with Src Inhibition of this interaction is useful for treatment or prophylaxis of neurological diseases and disorders, pain and cancer.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: NoNO Inc.
    Inventors: Michael Tymianski, Rongwen Li, Jonathan David Garman
  • SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOEITIN-2
    Publication number: 20140275479
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Application
    Filed: May 29, 2014
    Publication date: September 18, 2014
    Applicant: AMGEN INC.
    Inventors: Jonathan Daniel OLINER, Hosung MIN
  • IMMUNOLOGICALLY ACTIVE POLYPEPTIDE
    Publication number: 20140271652
    Abstract: Disclosed are immunomodulatory polypeptides that elicit an unusual induced cytokine profile, compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Institute of Arthritis Research, LLC
    Inventor: Craig D. Scoville
  • Methods for Detecting Ehrlichia Infection
    Publication number: 20140273026
    Abstract: The present invention provides an isolated and purified heat shock protein 60 (Hsp60) peptide having the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to a vaccine against Ehrlichia comprising a peptide homologous to the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to an antibody directed against a peptide homologous to the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to a method of determining whether a subject is infected with Ehrlichia, comprising the steps of: contacting a sample from a subject with the antibody described herein; and detecting a resulting antibody reaction, wherein a positive reaction indicates the subject is infected with Ehrlichia.
    Type: Application
    Filed: February 6, 2014
    Publication date: September 18, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: David H. Walker, Sunil Thomas
  • ADJUVANT COMPOSITIONS AND METHODS OF USING THEREOF
    Publication number: 20140271723
    Abstract: The present invention relates to adjuvant compositions, vaccine compositions, and methods of enhancing an immune response to an antigen.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Inventors: Shuan Shian Huang, Jung San Huang
  • INHIBITORS OF MITOCHONDRIAL FISSION AND METHODS OF USE THEREOF
    Publication number: 20140274904
    Abstract: The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to, evaluating the effects of the constructs and peptides on Drp1 GTPase activity, binding of Drp1 to Fis1, reduction of mitochondrial damage, reduction in cell death, inhibition of mitochondrial fragmentation in a cell under pathological conditions, and reduced loss of neurites in primary dopaminergic neurons in a Parkinsonism cell culture.
    Type: Application
    Filed: May 6, 2014
    Publication date: September 18, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Daria Mochly-Rosen, Xin Qi, Nir Qvit
  • NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY
    Publication number: 20140271692
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.
    Type: Application
    Filed: December 23, 2013
    Publication date: September 18, 2014
    Applicant: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Harpreet SINGH, Steffen WALTER, Toni WEINSCHENK, Norbert HILF, Oliver SCHOOR, Claudia TRAUTWEIN
  • IgG-BINDING PEPTIDE AND METHOD FOR DETECTING AND PURIFYING IgG USING SAME
    Publication number: 20140274790
    Abstract: Provided is a peptide that specifically or selectively binds to human IgG. This peptide comprises an amino acid sequence consisting of 13 to 17 amino acid residues and is capable of binding to human IgG, wherein the amino acid sequence is represented by formula I: (X1-3)-C-(X2)-H-R-G-(Xaa1)-L-V-W-C-(X1-3), wherein, X each independently represents any amino acid residue except cysteine, C represents a cysteine residue, H represents a histidine residue, R represents an arginine residue, G represents a glycine residue, Xaa1 represents a glutamic acid residue or an asparagine residue, L represents a leucine residue, V represents a valine residue, and W represents a tryptophan residue.
    Type: Application
    Filed: August 23, 2012
    Publication date: September 18, 2014
    Inventor: Yuji Ito
  • PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE
    Publication number: 20140271690
    Abstract: The present disclosure is directed to individual A? peptide immunogen constructs, peptide compositions comprising these A? peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations comprising these A? peptide immunogen constructs, with the individual A? peptide immunogen constructs having the N-terminus of the A? peptide as the B cell (B) epitopes linked through spacer residue(s) to heterologous T helper cell (Th) epitopes derived from pathogen proteins that act together to stimulate the generation of highly specific antibodies directed against the N-terminus of the A? peptide offering protective immune responses to patients at risk for, or with, Alzheimer's Disease.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: UNITED BIOMEDICAL, INC.
    Inventor: Chang Yi Wang
  • Agents for the treatment of celiac disease
    Patent number: 8835603
    Abstract: The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: September 16, 2014
    Assignee: ImmusanT, Inc.
    Inventors: Robert P. Anderson, Jessica A. Stewart, James A. Dromey, Jason A. Tye-Din
  • Natriuretic polypeptide delivery systems
    Patent number: 8835601
    Abstract: This document provides natriuretic polypeptide delivery systems. For example, methods and materials related to natriuretic polypeptide delivery systems, methods and materials related to the use of such delivery systems to deliver natriuretic polypeptides to a mammal over a pro-longed period of time (e.g., weeks to months), and methods and materials related to treating heart failure conditions are provided.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: September 16, 2014
    Assignees: Mayo Foundation for Medical Education and Research, Nanyang Technological University
    Inventors: Horng H. Chen, John C. Burnett, Jr., Lim Soo Ghim, Subramanian S. Venkatraman
  • Protein peptide hydrogels
    Patent number: 8835395
    Abstract: The present invention broadly provides novel peptides that can be used to form hydrogels. The peptides are short (preferably 30 amino acid residues or less) and include hydrophilic and hydrophobic segments joined by a turning segment. The hydrogels are formed by altering the pH of a solution of these peptides to an acidic level, or by introducing a source of ions into a solution of these peptides. The resulting hydrogels are shear thinning gels that have high storage moduli and high rates of recovery after destruction. They find use in medical applications, including tissue engineering.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: September 16, 2014
    Assignee: Kansas State University Research Foundation
    Inventors: Xiuzhi Susan Sun, Hongzhou Huang
  • Macromolecular diffusion and release from self-assembled ?-hairpin peptide hydrogels
    Patent number: 8834926
    Abstract: A hydrogel for delayed release of an anionic macromolecule, wherein the hydrogel comprises the anionic macromolecule, 150 mM NaCl, and a peptide selected from the group consisting of SEQ ID NO:1 through SEQ ID NO:33 in an aqueous medium at a pH of 7.4; wherein the anionic macromolecule has an isoelectric point of at most 6.8; and wherein the hydrogel is capable of retaining at least 25% of the anionic macromolecule after 28-day extraction at 37° C. with a pH=7.4 BTP buffer containing 150 mM NaCl.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: September 16, 2014
    Assignee: University of Delaware
    Inventors: Joel P. Schneidér, Monica C. Branco, Darrin J. Pochan, Norman J. Wagner
  • Antimicrobial peptide variants and polynucleotides encoding same
    Patent number: 8835604
    Abstract: The present invention relates to variants of a parent antimicrobial peptide. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: September 16, 2014
    Assignee: Adenium Biotech Aos
    Inventors: Hans-Henrik Kristensen Hoegenhaug, Per Holse Mygind, Thomas Kruse, Dorotea Raventos Segura, Dorthe Hoj Sandvang, Soren Neve
  • Compositions And Methods For Treating Glioma
    Publication number: 20140256628
    Abstract: Isolated peptides, compositions and methods of use for treating tumors infiltrated with macrophages, such as glioblastomas.
    Type: Application
    Filed: May 16, 2014
    Publication date: September 11, 2014
    Applicant: NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY
    Inventors: Bozena Kaminska-Kaczmarek, Malgorzata Sielska, Pawel Wisniewski, Aleksandra Ellert-Miklaszewska
  • MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY
    Publication number: 20140256596
    Abstract: The invention describes peptide ligands specific for human plasma Kallikrein.
    Type: Application
    Filed: October 8, 2012
    Publication date: September 11, 2014
    Applicant: BICYCLE THERAPEUTICS LIMITED
    Inventors: John Tite, Edward Walker, Catherine Stace, Daniel Teufel
  • ANTI-ANGIOGENIC MOLECULES, NANOSTRUCTURES AND USES THEREOF
    Publication number: 20140256635
    Abstract: The disclosure is generally directed toward the design and synthesis of peptide amphiphile (PA) molecules that comprises a peptide configured to inhibit angiogenesis. The peptide amphiphile comprises a hydrophobic tail, peptide sequence capable of beta-sheet formation; and a peptide, wherein the peptide is configured to inhibit angiogenesis. Optionally the PA further comprises a flexible linker between the peptide sequence capable of beta-sheet formation and the peptides. Further this disclosure is directed to nanostructures comprising peptide amphiphiles configured to inhibit angiogenesis.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 11, 2014
    Applicant: Northwestern University
    Inventors: Runye H. Zha, Ming Zhang, Samuel I. Stupp
  • Methods and Compositions Comprising a C-Terminal Bax Peptide
    Publication number: 20140255299
    Abstract: In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells.
    Type: Application
    Filed: August 24, 2012
    Publication date: September 11, 2014
    Applicant: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Annette Khaled, Rebecca Boohaker, Michael Lee, Jesus Perez Figueroa
  • METHOD FOR SYNTHESIZING PROTEINS
    Publication number: 20140256879
    Abstract: Method for assembling proteins from peptide fragments. It allows the production of proteins in a manner that is simple, reliable and applicable on an industrial scale. This method allows the production of proteins of therapeutic or diagnostic interest. Kits for applying this synthesis method as well as test and/or diagnostic kits are also described.
    Type: Application
    Filed: October 16, 2012
    Publication date: September 11, 2014
    Inventors: Oleg Melnyk, Laurent Raibaut, Vincent Aucagne, Agnes Delmas
  • Stabilized Variant MAML Peptides and Uses Thereof
    Publication number: 20140256912
    Abstract: Internally cross-linked peptides derived from human MAML and derivatives thereof which exhibit affinity for the ICN1-CSL complex are described and characterized. The peptides can interfere with NOTCH signaling and are thus useful for treating various disorders, including certain cancers.
    Type: Application
    Filed: June 15, 2012
    Publication date: September 11, 2014
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Raymond Earle Moellering, Gregory L. Verdine
  • RECEPTOR GENE FOR PEPTIDE CANCER ANTIGEN-SPECIFIC T CELL
    Publication number: 20140255941
    Abstract: The invention provides the nucleotide sequence and amino acid sequence of the CDR3 domain of the T cell receptor (TCR) gene of a WT1-specific cytotoxic T cell (CTL) against WT1 protein. Also provided are a method for testing for and treating cancer using the nucleotide sequence and amino acid sequence, and a chip, primer set, kit, and device for testing for cancer comprising the nucleotide sequence and amino acid sequence.
    Type: Application
    Filed: June 20, 2012
    Publication date: September 11, 2014
    Applicant: International Institute of Cancer Immunology, Inc.
    Inventor: Haruo Sugiyama
  • PEPTIDES WITH VIRAL INFECTION ENHANCING PROPERTIES AND THEIR USE
    Publication number: 20140255349
    Abstract: The invention relates to peptides and functional derivatives thereof and their use for improving transduction efficiency of viruses into target cells.
    Type: Application
    Filed: June 28, 2012
    Publication date: September 11, 2014
    Applicants: GENETHON, Institut National de la Sainte et de la recherche Madicale, Centre National de la Recherche Scientique
    Inventors: David Fenard, Antoine Kichler, Samia Martin
  • Treatments for Gastrointestinal Disorders
    Publication number: 20140256634
    Abstract: Described herein are peptides, compositions, and related methods for treating upper gastrointestinal disorders and conditions (e.g., dyspepsia, gastroparesis, post-operative gastric ileus, a functional esophageal disorder, a functional gastroduodenal disorder, gastroesophageal reflux disease (GERD), or a duodenal or stomach ulcer) as well as other conditions and disorders that are described herein.
    Type: Application
    Filed: May 23, 2014
    Publication date: September 11, 2014
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kessler, Brian Cali
  • ESTROGEN-RECEPTOR BASED LIGAND SYSTEM FOR REGULATING PROTEIN STABILITY
    Publication number: 20140255361
    Abstract: Disclosed herein are systems, methods and compositions for rapidly and reversibly destabilizing a target protein in vitro or in vivo, in the presence or absence of a cell-permeable, synthetic molecule or ligand.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 11, 2014
    Applicant: The Board of Trustees Of The Leland Stanford Junior University
    Inventors: Thomas J. Wandless, Ling-chun Chen
  • RECOMBINANT PROTEINS FOR USE IN VACCINE, ANTIBODIES AGAINST SAID PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC METHODS INCLUDING THE SAME
    Publication number: 20140248272
    Abstract: The present invention relates to proteins and/or fragments and derivatives thereof and their use as vaccines and in biotechnological methods. The vaccines particularly include immunogenic proteins in Treponema spp. isolated from digital dermatitis in cattle. The present invention further relates to antibodies raised against said proteins or fragments thereof, and the use of said proteins in diagnostic methods in which antibodies are detected as a sign of digital dermatitis in cattle.
    Type: Application
    Filed: March 4, 2014
    Publication date: September 4, 2014
    Inventors: Anna ROSANDER, Märit PRINGLE
  • QUANTIFICATION OF VACCINE COMPOSITIONS
    Publication number: 20140248603
    Abstract: The invention provides methods and mass-labeled peptides for use in said methods for quantifying the presence of a one or more viral proteins in a sample of a preparation containing agents which bind to said viral protein, using mass-spectroscopic analyses of the sample and standards containing known amounts of labeled and unlabeled signature peptides, in particular wherein said viral proteins are antigens in a vaccine for porcine circovirus.
    Type: Application
    Filed: February 28, 2014
    Publication date: September 4, 2014
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Marc Allan EICHMEYER, Michael B. ROOF, Merrill Lynn SCHAEFFER, Eric Martin VAUGHN, Kun YANG, Jeremy Richard RUSH, Daniel John MURFIN
  • Albumin variants
    Patent number: 8822417
    Abstract: Variants of a parent albumin having altered plasma half-life compared with a parent albumin are described. Fusion polypeptides and conjugates including the variant albumin are also described. Embodiments include, but are not limited to, a polypeptide which is a variant of albumin, including one or more alterations at one or more positions corresponding to 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120 in SEQ ID NO: 2.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: September 2, 2014
    Assignee: Novozymes Biopharma DIC A/S
    Inventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Delahay
  • Affinity peptides toward infliximab
    Patent number: 8822423
    Abstract: We have disclosed affinity peptides toward infliximab. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for infliximab.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: September 2, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: Daphne Ann Salick Ryan, John Kehoe, John Wheeler, Chunlin Yang, Abla Creasey
  • Peptides and aptamers thereof as specific modulators of mutant p53 function
    Patent number: 8822420
    Abstract: In the present application isolated peptides and aptamers thereof able to interact with structural and conformational p53 mutants within the region of the wild-type p53 DNA binding core domain comprised from amino acids 74 to amino acids 298 using the yeast two-hybrid method are disclosed. These PAs are able to efficiently recognize several different p53 point mutants but not wild-type p53. Therefore the peptides and aptamers identified can be useful as inhibitors of mutant p53-associated pro-oncogenic functions for anticancer therapy or as diagnostic tools for mut-p53 or wild-type p53 or as template for designing new peptido-mimetic drugs able to specifically target tumor cells.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: September 2, 2014
    Assignee: Universita Degli Studi di Trieste
    Inventors: Giannino Del Sal, Elisa Guida, Andrea Bisso
  • ARENAVIRUS INHIBITING PEPTIDES AND USES THEREFOR
    Publication number: 20140243256
    Abstract: The present invention describes peptides which inhibit fusion of an arenavirus (e.g., Pichinde virus; PICV) with a host cell membrane. The arenavirus inhibiting (AVI) peptides described herein comprise a segment of the GP2 protein of an arenavirus. The AVI peptides are useful for inhibiting arenavirus-to-host cell membrane fusion and for treating arenavirus infections. In a particular embodiment, the arenavirus inhibiting peptide comprises a segment of PICV glycoprotein 2 (PICV GP2; SEQ ID NO: 1), Tamiami virus (TAMV) GP2 (SEQ ID NO: 14), or Lassa virus (LASV) GP2 (SEQ ID NO: 15). In particular, the segment is selected from a region of an arenavirus GP2 extending from the N-terminus into the first half of the FIR (i.e., from residues 1 through 105 of SEQ ID NO: 1, SEQ ID NO: 14, or SEQ ID NO: 15).
    Type: Application
    Filed: March 14, 2013
    Publication date: August 28, 2014
    Applicant: The Administrators of the Tulane Educational Fund
    Inventors: Jennifer S. SPENCE, Robert F. GARRY
  • METHODS AND COMPOSITIONS FOR TARGETING ADIPOSE CELLS IN MAMMALS
    Publication number: 20140243258
    Abstract: Methods and compositions are presented for use in diagnostic, imaging or targeting of therapeutic agents to treat obesity/adiposity-associated disorders, where such as compositions and methods identify and use peptides to selectively target adipose tissue stromal cells in mammals, both in vitro and in vivo.
    Type: Application
    Filed: March 30, 2012
    Publication date: August 28, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Mikhail G. Kolonin, Alexes Daquinag, Yan Zhang
  • ERBB2 Peptides
    Publication number: 20140243268
    Abstract: Compositions that inhibit or block the interaction between Erbin and ErbB2 and methods of their use are provided. Preferred compositions include peptides that inhibit or block Erbin and ErbB2 interaction under physiologic conditions in a subject. One embodiment provides an isolated peptide fragment of ErbB2 including the C-terminal 15 amino acids of ErbB2. The peptide fragment can be about 15 to 27 amino acids in length.
    Type: Application
    Filed: February 24, 2014
    Publication date: August 28, 2014
    Applicant: Georgia Regents Research Institute, Inc.
    Inventors: Lin Mei, Wen-Cheng Xiong, Cheng-Yong Shen, Yan-Mei Tao, Shi-Wen Luo
  • PEPTIDE DERIVATIVES AND USE THEREOF AS CARRIERS FOR MOLECULES IN THE FORM OF CONJUGATES
    Publication number: 20140243499
    Abstract: The invention relates to peptide derivatives (peptides and pseudo-peptides) and use thereof as vectors for molecules of interest. The invention also relates to conjugates containing a peptide derivative of the invention bound to a molecule of interest. The peptides and prodrug conjugates of the invention can be used to vectorise molecules of pharmaceutical or diagnostic interest, such as, for example, therapeutic molecules, imaging or diagnostic agents, or molecular probes, across cell membranes, and notably to promote their transport across the blood-brain barrier (BBB).
    Type: Application
    Filed: May 14, 2014
    Publication date: August 28, 2014
    Applicants: Vect-Horus, Centre National De La Recherche Scientifique, Universite D'Aix Marseille
    Inventors: MICHEL KHRESTCHATISKY, MARION DAVID, YVES MOLINO, PATRICK VLIEGHE
  • JAML SPECIFIC BINDING AGENTS, ANTIBODIES, AND USES RELATED THERETO
    Publication number: 20140242068
    Abstract: Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto.
    Type: Application
    Filed: August 10, 2012
    Publication date: August 28, 2014
    Applicant: EMORY UNIVERSITY
    Inventors: Charles A. Parkos, Dominique A. Weber
  • Synthetic arginine substituted peptides and their use
    Patent number: 8815812
    Abstract: The present invention relates to new arginine substituted peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumors, pain, wounds and/or scars.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: August 26, 2014
    Assignee: Inger Mattsby-Baltzer
    Inventors: Inger Mattsby-Baltzer, Gunnar Dolphin
  • Fluorescent imaging agents
    Patent number: 8815214
    Abstract: Provided is a family of intramolecularly quenched imaging agents for use in both in vivo and in vitro imaging that contain at least one enzymatically cleavable oligopeptide and two fluorophores or a fluorophore and a quencher. When subjected to proteolytic cleavage, at least one fluorophore is unquenched and becomes capable of producing a fluorescent signal upon excitation with light of an appropriate wavelength. Also provided are in vivo and in vitro imaging methods using such imaging agents.
    Type: Grant
    Filed: January 17, 2009
    Date of Patent: August 26, 2014
    Assignee: VisEn Medical, Inc.
    Inventors: Milind Rajopadhye, Kevin Groves, Dorin V. Preda
  • Compositions and methods for CaMKII inhibitors and uses thereof
    Patent number: 8816046
    Abstract: Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: August 26, 2014
    Assignee: The University of Colorado, a body corporate
    Inventor: K. Ulrich Bayer
  • SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT
    Publication number: 20140235789
    Abstract: The present application discloses peptides and peptaibols of high purity may be obtained by solid phase peptide synthesis using as the starting resin hydroxy amino acids, hydroxy amino acid amides, hydroxy amino alcohols or small peptides containing hydroxy amino acids attached to polymers through their side chain.
    Type: Application
    Filed: February 21, 2013
    Publication date: August 21, 2014
    Applicant: Chemical & Biopharmaceutical Laboratories of Patras S.A.
    Inventor: Chemical & Biopharmaceutical Laboratories of Patras S.A.
  • USE FOR GLYCOLIPOPROTEIN GINTONIN, ISOLATED AND IDENTIFIED FROM GINSENG, AS A NATURAL MEDICAL-PLANT DERIVED LIGAND
    Publication number: 20140234868
    Abstract: The present invention relates to glycolipoprotein gintonin, isolated and identified from ginseng, as a natural medicinal-plant-derived ligand acting on LPA1 (lysophosphatidic acid; 1- or 2-acyl-sn-glycerol-3-phosphate), LPA2, LPA3, LPA4 and LPA5 receptors whose efficacy is exhibited physiologically/pharmaceutically via an interaction with subset receptors [LPA1(edg-2), LPA2(edg-4), LPA3(edg-7), LPA4, PLA5] in the EDG (endothelial differentiation gene) family in G protein-coupled receptors (GPCRs) present in the cell membranes of animals including humans.
    Type: Application
    Filed: September 19, 2012
    Publication date: August 21, 2014
    Applicant: KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP.
    Inventors: Seung Yeol Nah, Sung Hee Hwang, Tae Joon Shin, Sun Hye Choi
  • PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1
    Publication number: 20140234334
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.
    Type: Application
    Filed: July 9, 2013
    Publication date: August 21, 2014
    Applicant: AMGEN INC.
    Inventors: Hosung MIN, Hailing HSU, Fei XIONG
  • MICRODYSTROPHIN PEPTIDES AND METHODS FOR TREATING MUSCULAR DYSTROPHY USING THE SAME
    Publication number: 20140234255
    Abstract: According to the embodiments described herein, a series of biological materials for treatment/therapy of DMD and/or BMD through the recovery of sarcolemmal nNOS is provided. The biological material comprises the complete dystrophin repeats R16 and R17 or certain domains, sections, or fragments of the dystrophin repeats R16 and R17. In some aspects, such domains, sections, or fragments may be selected from sequence motifs including dystrophin R17 ?1 helix, ?2 and ?3 helices of both R16 and R17, or a combination thereof.
    Type: Application
    Filed: November 26, 2013
    Publication date: August 21, 2014
    Applicant: THE CURATORS OF THE UNIVERSITY OF MISSOURI
    Inventors: Yi Lai, Junling Zhao, Yongping Yue, Dongsheng Duan
  • METHODS AND COMPOSITIONS FOR MODULATING THE Wnt PATHWAY
    Publication number: 20140235820
    Abstract: The invention provides methods and compositions for modulating the Wnt signaling pathway, in particular by interfering with binding of Dkk1 or SOST with LRP5 and/or LRP6.
    Type: Application
    Filed: April 29, 2014
    Publication date: August 21, 2014
    Applicant: GENENTECH, INC.
    Inventors: Eric Bourhis, Andrea Cochran, Yingnan Zhang
  • MUC1, caspase-8, and DED-containing proteins
    Patent number: 8809002
    Abstract: The disclosure features a variety of compositions and methods for modulating an interaction between MUC1 and caspase-8 and/or an interaction between MUC1 and a DED-containing protein (e.g., an anti-apoptotic DED-containing protein or a pro-apoptotic DED-containing protein). Such methods and compositions are useful for the treatment or prevention of e.g., a variety of pathological disorders characterized by elevated or decreased levels of apoptosis. Moreover, the compositions and methods are also useful to identify, design, and generate compounds that modulate the interactions. The compounds and/or pharmaceutical compositions containing the compounds can be used in the treatment of disease.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: August 19, 2014
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventor: Donald W. Kufe
  • Peptoids and methods for treating alzheimer's disease
    Patent number: 8809275
    Abstract: Provided herein are peptoids capable of inhibiting or reversing amyloid ? (A?) fibril or plaque production. The peptoids form a helical structure with three monomers per helical turn and have at least two monomers with a side-chain having an arylalkyl group having the same chirality positioned such that the side-chains are on the same side of the peptoid. Also provided are methods of using the peptoids to inhibit or reverse aggregation of A? and methods of treating subjects with Alzheimer's disease (AD) or slowing the progression of AD.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: August 19, 2014
    Assignees: The Board of Trustees of the University of Arkansas, University of South Carolina
    Inventors: Shannon Servoss, Melissa Moss